홈 > 시장보고서 > 의약품 > 암

시장보고서

상품코드

1571501

NUT 정중선 암 치료 시장 규모, 점유율, 동향 분석 보고서 : 치료별, 투여 경로별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

NUT Midline Carcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy), By Route Of Administration (Oral), By End Use, By Region, And Segment Forecasts, 2024 - 2030

발행일: 2024년 09월 | 리서치사:

Grand View Research | 페이지 정보: 영문 120 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

NUT 정중선 암 치료 시장 성장과 동향:

Grand View Research, Inc.의 조사 보고서에 따르면, 세계 NUT 정중선 암 치료 시장 규모는 2030년까지 연평균 12.4%의 성장률로 441억 달러에 달할 것으로 예상됩니다.

이러한 성장의 주요 요인은 희귀 암종에 대한 인식의 증가, 표적 치료의 발전, 정밀 의학에 대한 관심의 증가에 기인합니다. 진단 도구의 발전과 의료 전문가들의 인식 향상으로 더 많은 사례가 조기에 발견되고 있으며, 이는 효과적인 치료에 대한 수요 증가로 이어지고 있습니다.

표적 치료제, 특히 후성유전학적 기전에 초점을 맞춘 치료제의 등장은 이 시장에서 매우 중요합니다. 예를 들어, NMC와 밀접한 관련이 있는 BRD4-NUT 융합 단백질을 표적으로 하는 BET(브로모도메인 및 엑스트라 터미널) 억제제의 개발은 새로운 치료의 길을 열어주었습니다. 브리스톨 마이어스 스퀴브(Bristol-Myers Squibb) 등은 이 조사의 최전선에 있으며, 현재 임상시험 중인 트로타블레시브(CC-90010)와 같은 약물을 개발하고 있습니다. 이 질환의 공격성과 나쁜 예후로 인해 새로운 치료법 개발이 절실히 요구되고 있습니다. 이 질환은 희귀한 질환이기 때문에 임상시험을 위한 환자 수가 제한되어 있고, 종합적인 역학 데이터가 부족한 등 여러 가지 어려움이 있습니다.

정부와 규제기관도 NMC 치료제 개발을 가속화하는 데 중요한 역할을 하고 있습니다. 미국과 유럽을 포함한 많은 지역에서 NMC는 희귀질환으로 지정되어 있으며, 희귀암 치료제를 개발하는 기업에게 세액공제, 시장 독점권 연장 등의 인센티브를 제공하고 있습니다. 이러한 인센티브는 환자 수가 적어 제한적인 NMC 연구에 대한 투자를 촉진하는 데 매우 중요합니다.

NUT 정중선 암 치료 시장 보고서 하이라이트

2023년 화학요법 부문은 NUT 정중선 암 치료 시장에서 32.5%의 가장 큰 매출 점유율을 차지했습니다.
정맥 내 부문은 2023년 68.7%의 가장 큰 매출 점유율을 차지했습니다. 이는 높은 생체 이용률과 혈류로의 빠른 약물전달을 통해 강력한 치료제가 종양 세포에 도달할 수 있도록 보장하기 때문에 NMC 관리에서 속효성 치료의 필요성에 의해 주도되고 있습니다. 경구용 약물보다 더 효과적입니다.
전문 클리닉은 예측 기간 동안 13.5%의 CAGR을 달성할 것으로 예상됩니다.

지역별 - 대시보드
시장 규모와 예측 동향 분석, 2018-2030년 :
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 노르웨이
- 스웨덴
- 덴마크
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트

제8장 경쟁 상황

기업/경쟁 분류
벤더 상황
- 주요 판매대리점 및 채널 파트너 리스트
- 주요 기업의 시장 점유율 분석, 2023년
- Merck &Co. Inc
- Bristol-Myers Squibb Company
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- C4 Therapeutics, Inc.
- Ipsen Biopharmaceuticals, Inc
- GSK plc

ksm 24.11.01

NUT Midline Carcinoma Treatment Market Growth & Trends:

The global NUT midline carcinoma treatment market size is anticipated to reach USD 44.1 billion by 2030, growing at a CAGR of 12.4%, according to a report by Grand View Research, Inc. This significant growth is majorly driven by the increasing awareness of rare cancer types, advancements in targeted therapies, and the growing focus on precision medicine. With advancements in diagnostic tools and greater awareness among healthcare professionals, more cases are being identified earlier, leading to an increased demand for effective treatments.

The rise of targeted therapies, particularly those focusing on epigenetic mechanisms, has been pivotal in this market. For instance, the development of BET (bromodomain and extra-terminal) inhibitors, which target the BRD4-NUT fusion protein commonly associated with NMC, has opened new avenues for treatment. Companies such as Bristol-Myers Squibb are at the forefront of this research, developing drugs such as Trotabresib (CC-90010), which are currently in clinical trials. The aggressive nature of the disease and the poor prognosis associated with it create a strong imperative for the development of new therapies. The rarity of the disease also presents challenges, including limited patient pools for clinical trials and a lack of comprehensive epidemiological data.

Government and regulatory bodies are also playing a crucial role in accelerating the development of NMC treatments. In many regions, including the U.S. and Europe, NMC has been granted orphan disease status, providing incentives such as tax credits and extended market exclusivity to companies developing treatments for this rare cancer. These incentives are critical in encouraging investment in NMC research, which is otherwise limited due to the small patient population.

NUT Midline Carcinoma Treatment Market Report Highlights:

In 2023, the chemotherapy segment accounted for the largest revenue share of 32.5% in NUT midline carcinoma treatment market.
The intravenous segment accounts for the largest revenue share of 68.7% in 2023 driven by the need for fast-acting treatments in managing NMC due to its higher bioavailability and quicker delivery of the drug to the bloodstream, ensuring that the potent therapies reach the tumor cells more effectively than oral medications might.
Specialty clinics are anticipated to achieve the highest CAGR of 13.5% during the forecast period.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Treatment
- 1.2.2. Route of Administration
- 1.2.3. End Use
- 1.2.4. Regional scope
- 1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
  - 1.4.5.1. Data for primary interviews in North America
  - 1.4.5.2. Data for primary interviews in Europe
  - 1.4.5.3. Data for primary interviews in Asia Pacific
  - 1.4.5.4. Data for primary interviews in Latin America
  - 1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Treatment Outlook
- 2.2.2. Route of Administration
- 2.2.3. End Use
- 2.2.4. Regional outlook
2.3. Competitive Insights

Chapter 3. NUT midline carcinoma Treatment Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
- 3.2.1. Market driver analysis
  - 3.2.1.1. Rising Prevalence NUT Midline Carcinoma
  - 3.2.1.2. Advancement in Diagnostics
- 3.2.2. Market restraint analysis
  - 3.2.2.1. High Diagnostic Challenges
  - 3.2.2.2. Limited Awareness
3.3. NUT midline carcinoma Treatment Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Supplier power
  - 3.3.1.2. Buyer power
  - 3.3.1.3. Substitution threat
  - 3.3.1.4. Threat of new entrant
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political landscape
  - 3.3.2.2. Technological landscape
  - 3.3.2.3. Economic landscape

Chapter 4. NUT midline carcinoma Treatment Market: Treatment Estimates & Trend Analysis

4.1. Global NUT midline carcinoma Treatment Market: Treatment Dashboard
4.2. Global NUT midline carcinoma Treatment Market: Treatment Movement Analysis
4.3. Global NUT midline carcinoma Treatment Market by Treatment, Revenue
4.4. Chemotherapy
- 4.4.1. Chemotherapy market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Targeted Therapy
- 4.5.1. Targeted Therapy market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Immunotherapy
- 4.6.1. Immunotherapy market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Radiation Therapy
- 4.7.1. Radiation Therapy market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Others
- 4.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. NUT midline carcinoma Treatment Market: Route of Administration Estimates & Trend Analysis

5.1. Global NUT midline carcinoma Treatment Market: Route of Administration Dashboard
5.2. Global NUT midline carcinoma Treatment Market: Route of Administration Movement Analysis
5.3. Global NUT midline carcinoma Treatment Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
5.4. Oral
- 5.4.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Intravenous
- 5.5.1. Intravenous market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Other
- 5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. NUT midline carcinoma Treatment Market: End Use Estimates & Trend Analysis

6.1. Global NUT midline carcinoma Treatment Market: End Use Dashboard
6.2. Global NUT midline carcinoma Treatment Market: End Use Movement Analysis
6.3. Global NUT midline carcinoma Treatment Market Estimates and Forecasts, By End Use, Revenue (USD Million)
6.4. Hospitals
- 6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Specialty Clinics
- 6.5.1. Specialty clinics market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Other
- 6.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. NUT midline carcinoma Treatment Market: Regional Estimates & Trend Analysis

7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
- 7.3.1. U.S.
  - 7.3.1.1. Key country dynamics
  - 7.3.1.2. Regulatory framework/ reimbursement structure
  - 7.3.1.3. Competitive scenario
  - 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 7.3.2. Canada
  - 7.3.2.1. Key country dynamics
  - 7.3.2.2. Regulatory framework/ reimbursement structure
  - 7.3.2.3. Competitive scenario
  - 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 7.3.3. Mexico
  - 7.3.3.1. Key country dynamics
  - 7.3.3.2. Regulatory framework/ reimbursement structure
  - 7.3.3.3. Competitive scenario
  - 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
- 7.4.1. UK
  - 7.4.1.1. Key country dynamics
  - 7.4.1.2. Regulatory framework/ reimbursement structure
  - 7.4.1.3. Competitive scenario
  - 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.2. Germany
  - 7.4.2.1. Key country dynamics
  - 7.4.2.2. Regulatory framework/ reimbursement structure
  - 7.4.2.3. Competitive scenario
  - 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.3. France
  - 7.4.3.1. Key country dynamics
  - 7.4.3.2. Regulatory framework/ reimbursement structure
  - 7.4.3.3. Competitive scenario
  - 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.4. Italy
  - 7.4.4.1. Key country dynamics
  - 7.4.4.2. Regulatory framework/ reimbursement structure
  - 7.4.4.3. Competitive scenario
  - 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.5. Spain
  - 7.4.5.1. Key country dynamics
  - 7.4.5.2. Regulatory framework/ reimbursement structure
  - 7.4.5.3. Competitive scenario
  - 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.6. Norway
  - 7.4.6.1. Key country dynamics
  - 7.4.6.2. Regulatory framework/ reimbursement structure
  - 7.4.6.3. Competitive scenario
  - 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.7. Sweden
  - 7.4.7.1. Key country dynamics
  - 7.4.7.2. Regulatory framework/ reimbursement structure
  - 7.4.7.3. Competitive scenario
  - 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.8. Denmark
  - 7.4.8.1. Key country dynamics
  - 7.4.8.2. Regulatory framework/ reimbursement structure
  - 7.4.8.3. Competitive scenario
  - 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
- 7.5.1. Japan
  - 7.5.1.1. Key country dynamics
  - 7.5.1.2. Regulatory framework/ reimbursement structure
  - 7.5.1.3. Competitive scenario
  - 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.2. China
  - 7.5.2.1. Key country dynamics
  - 7.5.2.2. Regulatory framework/ reimbursement structure
  - 7.5.2.3. Competitive scenario
  - 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.3. India
  - 7.5.3.1. Key country dynamics
  - 7.5.3.2. Regulatory framework/ reimbursement structure
  - 7.5.3.3. Competitive scenario
  - 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.4. Australia
  - 7.5.4.1. Key country dynamics
  - 7.5.4.2. Regulatory framework/ reimbursement structure
  - 7.5.4.3. Competitive scenario
  - 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.5. South Korea
  - 7.5.5.1. Key country dynamics
  - 7.5.5.2. Regulatory framework/ reimbursement structure
  - 7.5.5.3. Competitive scenario
  - 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.6. Thailand
  - 7.5.6.1. Key country dynamics
  - 7.5.6.2. Regulatory framework/ reimbursement structure
  - 7.5.6.3. Competitive scenario
  - 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
- 7.6.1. Brazil
  - 7.6.1.1. Key country dynamics
  - 7.6.1.2. Regulatory framework/ reimbursement structure
  - 7.6.1.3. Competitive scenario
  - 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.2. Argentina
  - 7.6.2.1. Key country dynamics
  - 7.6.2.2. Regulatory framework/ reimbursement structure
  - 7.6.2.3. Competitive scenario
  - 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
- 7.7.1. South Africa
  - 7.7.1.1. Key country dynamics
  - 7.7.1.2. Regulatory framework/ reimbursement structure
  - 7.7.1.3. Competitive scenario
  - 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.2. Saudi Arabia
  - 7.7.2.1. Key country dynamics
  - 7.7.2.2. Regulatory framework/ reimbursement structure
  - 7.7.2.3. Competitive scenario
  - 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.3. UAE
  - 7.7.3.1. Key country dynamics
  - 7.7.3.2. Regulatory framework/ reimbursement structure
  - 7.7.3.3. Competitive scenario
  - 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.4. Kuwait
  - 7.7.4.1. Key country dynamics
  - 7.7.4.2. Regulatory framework/ reimbursement structure
  - 7.7.4.3. Competitive scenario
  - 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Company/Competition Categorization
8.2. Vendor Landscape
- 8.2.1. List of key distributors and channel partners
- 8.2.2. Key company market share analysis, 2023
- 8.2.3. Merck & Co. Inc
  - 8.2.3.1. Company overview
  - 8.2.3.2. Financial performance
  - 8.2.3.3. Product benchmarking
  - 8.2.3.4. Strategic initiatives
- 8.2.4. Bristol-Myers Squibb Company
  - 8.2.4.1. Company overview
  - 8.2.4.2. Financial performance
  - 8.2.4.3. Product benchmarking
  - 8.2.4.4. Strategic initiatives
- 8.2.5. Pfizer Inc.
  - 8.2.5.1. Company overview
  - 8.2.5.2. Financial performance
  - 8.2.5.3. Product benchmarking
  - 8.2.5.4. Strategic initiatives
- 8.2.6. F. Hoffmann-La Roche Ltd
  - 8.2.6.1. Company overview
  - 8.2.6.2. Financial performance
  - 8.2.6.3. Product benchmarking
  - 8.2.6.4. Strategic initiatives
- 8.2.7. C4 Therapeutics, Inc.
  - 8.2.7.1. Company overview
  - 8.2.7.2. Financial performance
  - 8.2.7.3. Product benchmarking
  - 8.2.7.4. Strategic initiatives
- 8.2.8. Ipsen Biopharmaceuticals, Inc
  - 8.2.8.1. Company overview
  - 8.2.8.2. Financial performance
  - 8.2.8.3. Product benchmarking
  - 8.2.8.4. Strategic initiatives
- 8.2.9. GSK plc
  - 8.2.9.1. Company overview
  - 8.2.9.2. Financial performance
  - 8.2.9.3. Product benchmarking
  - 8.2.9.4. Strategic initiatives

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 5,950

￦ 8,572,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 6,950

￦ 10,013,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

US $ 8,950

￦ 12,895,000

※ 부가세 별도

NUT 정중선 암 치료 시장 규모, 점유율, 동향 분석 보고서 : 치료별, 투여 경로별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

NUT Midline Carcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy), By Route Of Administration (Oral), By End Use, By Region, And Segment Forecasts, 2024 - 2030

NUT 정중선 암 치료 시장 성장과 동향:

NUT 정중선 암 치료 시장 보고서 하이라이트

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 NUT 정중선 암 치료 시장 변수, 동향, 범위

제4장 NUT 정중선 암 치료 시장 : 치료별 추정·동향 분석

제5장 NUT 정중선 암 치료 시장 : 투여 경로별 추정·동향 분석

제6장 NUT 정중선 암 치료 시장 : 최종 용도별 추정·동향 분석

제7장 NUT 정중선 암 치료 시장 : 지역별 추정·동향 분석